Predicting EGFR T790M mutation in brain metastases using multisequence MRI-based radiomics signature
Y Li, X Lv, B Wang, Z Xu, Y Wang, M Sun, D Hou - Academic Radiology, 2023 - Elsevier
Rationale and Objectives Timely identifying T790M mutation for non-small cell lung cancer
(NSCLC) patients with brain metastases (BM) is essential to adjust targeted treatment …
(NSCLC) patients with brain metastases (BM) is essential to adjust targeted treatment …
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors: A Nonrandomized Controlled Trial
Importance EGFR-variant non–small cell lung cancer (NSCLC) is associated with a high rate
of central nervous system (CNS) metastases, even with treatment with first-generation or …
of central nervous system (CNS) metastases, even with treatment with first-generation or …
Complete response in a lung adenocarcinoma with pleural metastases initially treated with gefitinib and switched to osimertinib after cerebral oligo-progression with …
M Hachlaf, S Lkhoyaali, W Nadir, H Lemsyeh… - Journal of Medical Case …, 2024 - Springer
Background First-and second-generation anti-epithelial growth factor receptor tyrosine
kinase inhibitors have shown great efficacy in the treatment of advanced adenocarcinoma …
kinase inhibitors have shown great efficacy in the treatment of advanced adenocarcinoma …
MS4A3 promotes the chemosensitivity of lung cancer via THAP1/EGFR pathways
Z Duan - Critical Reviews™ in Eukaryotic Gene Expression, 2024 - dl.begellhouse.com
ABSTRACT MS4A3 functions as a tumor suppressor in multiple cancer types. However, the
roles of MS4A3 in lung cancer are still unknown. Therefore, this study aims to investigate the …
roles of MS4A3 in lung cancer are still unknown. Therefore, this study aims to investigate the …